141 results
Page 3 of 8
424B5
qtd bv3837git1h
19 Mar 10
Prospectus supplement for primary offering
12:00am
424B5
xyjbzzheo4 hizl
17 Mar 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
tql2dgy9vwsecpow7
20 Jan 10
Regulation FD Disclosure
12:00am
8-K
EX-99.1
dshpu8e6
14 Jan 10
Regulation FD Disclosure
12:00am
8-K
EX-99
k7kp2kj5cmdznwan892n
23 Jul 09
Results of Operations and Financial Condition
12:00am
S-3
23lwlc
23 Jul 09
Shelf registration
12:00am
8-K
EX-99
40gn5g e00p
24 Apr 09
Regulation FD Disclosure
12:00am
8-K
EX-99
jaxlqtf9 2k1yd
22 Apr 09
Results of Operations and Financial Condition
12:00am
8-K
EX-99
cuenzx6dnlfmca05k cq
6 Apr 09
Regulation FD Disclosure
12:00am
8-K
EX-99
k6b m8a11h5hjp9k2qf
26 Feb 09
Regulation FD Disclosure
12:00am
8-K
EX-99
pg7dzew4urp
12 Feb 09
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
s6abec3
4 Feb 09
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
12:00am
8-K
EX-99
kq3l9z 8tfw
26 Jan 09
Regulation FD Disclosure
12:00am
8-K
EX-99.1
va46gpn
22 Dec 08
GSK and Theravance Announce Positive Phase 2b Results for LABA ‘444 in the Treatment of COPD in the Horizon Development Programme
12:00am
8-K
EX-99.1
urayjb3fjk7balh8
2 Dec 08
Initial results demonstrate potential of ‘444 in the treatment of patients with moderate to severe asthma
12:00am